Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSLV-132 in Long COVID
NCT04944121Phase 2Completed
- Sponsor
- Resolve Therapeutics
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of RSLV-132 in post acute COVID-19 syndrome, sponsored by Resolve Therapeutics. Started Jun 2021; status: completed.
02
Drugs
RSLV-132
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT04944121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944121.